Immutep's LAG-3 Agonist Shows Promise in Phase I Trial for Autoimmune Diseases
Event summary
- Immutep completed the single ascending dose (SAD) portion of its Phase I study for IMP761, a LAG-3 agonist antibody, with dosing up to 14 mg/kg.
- IMP761 was well tolerated across all dose levels with no safety concerns observed.
- The study is progressing to the multiple ascending dose (MAD) portion, expected to complete in Q3 2026.
- Data will be presented at the EULAR conference on June 4, 2026.
- IMP761 aims to selectively silence pathogenic T cells in autoimmune diseases, targeting conditions like rheumatoid arthritis and multiple sclerosis.
The big picture
Immutep's IMP761 represents a novel approach to treating autoimmune diseases by leveraging LAG-3 agonism to restore immune tolerance. The successful completion of the SAD portion of the Phase I trial positions the company to potentially capitalize on the growing demand for targeted immunotherapies. The autoimmune disease market, encompassing conditions like rheumatoid arthritis and multiple sclerosis, is a high-value sector with significant unmet needs, making IMP761 a strategic asset for Immutep's pipeline.
What we're watching
- Clinical Progression
- The pace at which Immutep advances IMP761 into Phase II trials will determine its competitive positioning in the autoimmune disease space.
- Market Potential
- Whether IMP761 can differentiate itself in a crowded field of autoimmune therapies targeting large, multi-billion-dollar markets.
- Regulatory Pathway
- How the safety and efficacy data from Phase I will influence regulatory strategies for future approvals.
Related topics